Does the media refer more to VCEL or APGE?

In the previous week, Apogee Therapeutics had 5 more articles in the media than Vericel. MarketBeat recorded 11 mentions for Apogee Therapeutics and 6 mentions for Vericel. Vericel's average media sentiment score of 1.79 beat Apogee Therapeutics' score of 1.64 indicating that Vericel is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Vericel 5 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Apogee Therapeutics 9 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive

Which has stronger valuation & earnings, VCEL or TGTX?

TG Therapeutics has higher revenue and earnings than Vericel. TG Therapeutics is trading at a lower price-to-earnings ratio than Vericel, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Vericel $276.26M 7.59 $16.52M $0.47 87.13 TG Therapeutics $799.54M 10.32 $447.18M $2.74 19.68

Is VCEL or TGTX more profitable?

TG Therapeutics has a net margin of 55.22% compared to Vericel's net margin of 7.91%. TG Therapeutics' return on equity of 73.49% beat Vericel's return on equity. Company Net Margins Return on Equity Return on Assets Vericel 7.91% 6.91% 5.02% TG Therapeutics 55.22% 73.49% 34.14%

Does the media refer more to VCEL or TGTX?

In the previous week, TG Therapeutics had 2 more articles in the media than Vericel. MarketBeat recorded 8 mentions for TG Therapeutics and 6 mentions for Vericel. Vericel's average media sentiment score of 1.79 beat TG Therapeutics' score of 1.19 indicating that Vericel is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Vericel 5 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive TG Therapeutics 5 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has higher valuation and earnings, IBRX or VCEL?

Vericel has higher revenue and earnings than ImmunityBio. ImmunityBio is trading at a lower price-to-earnings ratio than Vericel, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio ImmunityBio $165.79M 51.46 -$351.40M -$0.97 N/A Vericel $276.26M 7.59 $16.52M $0.47 87.13

Is IBRX or VCEL more profitable?

Vericel has a net margin of 7.91% compared to ImmunityBio's net margin of -598.55%. Vericel's return on equity of 6.91% beat ImmunityBio's return on equity. Company Net Margins Return on Equity Return on Assets ImmunityBio -598.55% N/A -51.65% Vericel 7.91% 6.91% 5.02%

Does the media favor IBRX or VCEL?

In the previous week, ImmunityBio had 3 more articles in the media than Vericel. MarketBeat recorded 9 mentions for ImmunityBio and 6 mentions for Vericel. Vericel's average media sentiment score of 1.79 beat ImmunityBio's score of 0.61 indicating that Vericel is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment ImmunityBio 2 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Positive Vericel 5 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive

Which has stronger valuation and earnings, VCEL or ALKS?

Alkermes has higher revenue and earnings than Vericel. Vericel is trading at a lower price-to-earnings ratio than Alkermes, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Vericel $276.26M 7.59 $16.52M $0.47 87.13 Alkermes $1.48B 5.39 $241.66M $0.38 124.76

Is VCEL or ALKS more profitable?

Vericel has a net margin of 7.91% compared to Alkermes' net margin of 3.96%. Vericel's return on equity of 6.91% beat Alkermes' return on equity. Company Net Margins Return on Equity Return on Assets Vericel 7.91% 6.91% 5.02% Alkermes 3.96% 4.15% 2.19%

Does the media refer more to VCEL or ALKS?

In the previous week, Alkermes had 1 more articles in the media than Vericel. MarketBeat recorded 7 mentions for Alkermes and 6 mentions for Vericel. Vericel's average media sentiment score of 1.79 beat Alkermes' score of 0.63 indicating that Vericel is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Vericel 5 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Alkermes 2 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to RYTM or VCEL?

In the previous week, Rhythm Pharmaceuticals had 8 more articles in the media than Vericel. MarketBeat recorded 14 mentions for Rhythm Pharmaceuticals and 6 mentions for Vericel. Vericel's average media sentiment score of 1.79 beat Rhythm Pharmaceuticals' score of 1.44 indicating that Vericel is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Rhythm Pharmaceuticals 11 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Vericel 5 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive

Vericel (VCEL) Competitors

$40.95 -0.23 (-0.56%)

As of 08/28/2026 04:00 PM Eastern

Compare

VCEL vs. APGE, TGTX, IBRX, ALKS, and RYTM

Should you buy Vericel stock or one of its competitors? Vericel's main competitors and comparable companies include Apogee Therapeutics (APGE), TG Therapeutics (TGTX), ImmunityBio (IBRX), Alkermes (ALKS), and Rhythm Pharmaceuticals (RYTM). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Vericel compare to Apogee Therapeutics?

Vericel (NASDAQ:VCEL) and Apogee Therapeutics (NASDAQ:APGE) are both mid-cap healthcare companies, but which is the better investment? We will compare the two companies based on the strength of their analyst recommendations, risk, media sentiment, profitability, dividends, valuation, institutional ownership and earnings.

Vericel currently has a consensus target price of $58.40, suggesting a potential upside of 42.61%. Apogee Therapeutics has a consensus target price of $126.77, suggesting a potential downside of 6.07%. Given Vericel's stronger consensus rating and higher possible upside, analysts plainly believe Vericel is more favorable than Apogee Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Vericel	0 Sell rating(s)	3 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.57
Apogee Therapeutics	1 Sell rating(s)	15 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.16

In the previous week, Apogee Therapeutics had 5 more articles in the media than Vericel. MarketBeat recorded 11 mentions for Apogee Therapeutics and 6 mentions for Vericel. Vericel's average media sentiment score of 1.79 beat Apogee Therapeutics' score of 1.64 indicating that Vericel is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Vericel	5 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive
Apogee Therapeutics	9 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive

Vericel has a net margin of 7.91% compared to Apogee Therapeutics' net margin of 0.00%. Vericel's return on equity of 6.91% beat Apogee Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Vericel	7.91%	6.91%	5.02%
Apogee Therapeutics	N/A	-29.88%	-28.08%

Vericel has higher revenue and earnings than Apogee Therapeutics. Apogee Therapeutics is trading at a lower price-to-earnings ratio than Vericel, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Vericel	$276.26M	7.59	$16.52M	$0.47	87.13
Apogee Therapeutics	N/A	N/A	-$255.84M	-$4.34	N/A

Vericel has a beta of 1.06, indicating that its share price is 6% more volatile than the broader market. Comparatively, Apogee Therapeutics has a beta of 0.34, indicating that its share price is 66% less volatile than the broader market.

79.0% of Apogee Therapeutics shares are owned by institutional investors. 7.6% of Vericel shares are owned by company insiders. Comparatively, 24.3% of Apogee Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Summary

Vericel beats Apogee Therapeutics on 12 of the 16 factors compared between the two stocks.

How does Vericel compare to TG Therapeutics?

Vericel (NASDAQ:VCEL) and TG Therapeutics (NASDAQ:TGTX) are both mid-cap healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their profitability, institutional ownership, earnings, valuation, media sentiment, dividends, analyst recommendations and risk.

In the previous week, TG Therapeutics had 2 more articles in the media than Vericel. MarketBeat recorded 8 mentions for TG Therapeutics and 6 mentions for Vericel. Vericel's average media sentiment score of 1.79 beat TG Therapeutics' score of 1.19 indicating that Vericel is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Vericel	5 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive
TG Therapeutics	5 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Vericel currently has a consensus target price of $58.40, indicating a potential upside of 42.61%. TG Therapeutics has a consensus target price of $63.00, indicating a potential upside of 16.82%. Given Vericel's stronger consensus rating and higher probable upside, equities research analysts clearly believe Vericel is more favorable than TG Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Vericel	0 Sell rating(s)	3 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.57
TG Therapeutics	1 Sell rating(s)	3 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.44

TG Therapeutics has higher revenue and earnings than Vericel. TG Therapeutics is trading at a lower price-to-earnings ratio than Vericel, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Vericel	$276.26M	7.59	$16.52M	$0.47	87.13
TG Therapeutics	$799.54M	10.32	$447.18M	$2.74	19.68

TG Therapeutics has a net margin of 55.22% compared to Vericel's net margin of 7.91%. TG Therapeutics' return on equity of 73.49% beat Vericel's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Vericel	7.91%	6.91%	5.02%
TG Therapeutics	55.22%	73.49%	34.14%

58.6% of TG Therapeutics shares are held by institutional investors. 7.6% of Vericel shares are held by company insiders. Comparatively, 8.9% of TG Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Vericel has a beta of 1.06, suggesting that its share price is 6% more volatile than the broader market. Comparatively, TG Therapeutics has a beta of 1.62, suggesting that its share price is 62% more volatile than the broader market.

Summary

TG Therapeutics beats Vericel on 12 of the 16 factors compared between the two stocks.

How does Vericel compare to ImmunityBio?

ImmunityBio (NASDAQ:IBRX) and Vericel (NASDAQ:VCEL) are both mid-cap healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their profitability, risk, institutional ownership, earnings, dividends, analyst recommendations, valuation and media sentiment.

Vericel has higher revenue and earnings than ImmunityBio. ImmunityBio is trading at a lower price-to-earnings ratio than Vericel, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ImmunityBio	$165.79M	51.46	-$351.40M	-$0.97	N/A
Vericel	$276.26M	7.59	$16.52M	$0.47	87.13

Vericel has a net margin of 7.91% compared to ImmunityBio's net margin of -598.55%. Vericel's return on equity of 6.91% beat ImmunityBio's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
ImmunityBio	-598.55%	N/A	-51.65%
Vericel	7.91%	6.91%	5.02%

ImmunityBio has a beta of 0.03, meaning that its stock price is 97% less volatile than the broader market. Comparatively, Vericel has a beta of 1.06, meaning that its stock price is 6% more volatile than the broader market.

8.6% of ImmunityBio shares are held by institutional investors. 66.1% of ImmunityBio shares are held by company insiders. Comparatively, 7.6% of Vericel shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

ImmunityBio presently has a consensus target price of $14.20, indicating a potential upside of 76.40%. Vericel has a consensus target price of $58.40, indicating a potential upside of 42.61%. Given ImmunityBio's stronger consensus rating and higher possible upside, equities research analysts clearly believe ImmunityBio is more favorable than Vericel.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
ImmunityBio	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.71
Vericel	0 Sell rating(s)	3 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.57

In the previous week, ImmunityBio had 3 more articles in the media than Vericel. MarketBeat recorded 9 mentions for ImmunityBio and 6 mentions for Vericel. Vericel's average media sentiment score of 1.79 beat ImmunityBio's score of 0.61 indicating that Vericel is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
ImmunityBio	2 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Positive
Vericel	5 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive

Summary

Vericel beats ImmunityBio on 9 of the 16 factors compared between the two stocks.

How does Vericel compare to Alkermes?

Vericel (NASDAQ:VCEL) and Alkermes (NASDAQ:ALKS) are both mid-cap healthcare companies, but which is the superior business? We will contrast the two businesses based on the strength of their risk, dividends, earnings, valuation, institutional ownership, profitability, analyst recommendations and media sentiment.

Vericel has a net margin of 7.91% compared to Alkermes' net margin of 3.96%. Vericel's return on equity of 6.91% beat Alkermes' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Vericel	7.91%	6.91%	5.02%
Alkermes	3.96%	4.15%	2.19%

In the previous week, Alkermes had 1 more articles in the media than Vericel. MarketBeat recorded 7 mentions for Alkermes and 6 mentions for Vericel. Vericel's average media sentiment score of 1.79 beat Alkermes' score of 0.63 indicating that Vericel is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Vericel	5 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive
Alkermes	2 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Vericel currently has a consensus price target of $58.40, suggesting a potential upside of 42.61%. Alkermes has a consensus price target of $54.56, suggesting a potential upside of 15.09%. Given Vericel's higher probable upside, research analysts clearly believe Vericel is more favorable than Alkermes.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Vericel	0 Sell rating(s)	3 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.57
Alkermes	1 Sell rating(s)	4 Hold rating(s)	12 Buy rating(s)	1 Strong Buy rating(s)	2.72

Vericel has a beta of 1.06, meaning that its stock price is 6% more volatile than the broader market. Comparatively, Alkermes has a beta of 0.34, meaning that its stock price is 66% less volatile than the broader market.

95.2% of Alkermes shares are owned by institutional investors. 7.6% of Vericel shares are owned by company insiders. Comparatively, 4.6% of Alkermes shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Alkermes has higher revenue and earnings than Vericel. Vericel is trading at a lower price-to-earnings ratio than Alkermes, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Vericel	$276.26M	7.59	$16.52M	$0.47	87.13
Alkermes	$1.48B	5.39	$241.66M	$0.38	124.76

Summary

Vericel beats Alkermes on 9 of the 17 factors compared between the two stocks.

How does Vericel compare to Rhythm Pharmaceuticals?

Rhythm Pharmaceuticals (NASDAQ:RYTM) and Vericel (NASDAQ:VCEL) are both mid-cap healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their institutional ownership, media sentiment, valuation, earnings, analyst recommendations, profitability, risk and dividends.

Vericel has a net margin of 7.91% compared to Rhythm Pharmaceuticals' net margin of -85.59%. Vericel's return on equity of 6.91% beat Rhythm Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Rhythm Pharmaceuticals	-85.59%	-159.87%	-44.00%
Vericel	7.91%	6.91%	5.02%

Rhythm Pharmaceuticals presently has a consensus price target of $141.12, suggesting a potential upside of 31.68%. Vericel has a consensus price target of $58.40, suggesting a potential upside of 42.61%. Given Vericel's higher possible upside, analysts clearly believe Vericel is more favorable than Rhythm Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Rhythm Pharmaceuticals	1 Sell rating(s)	3 Hold rating(s)	15 Buy rating(s)	0 Strong Buy rating(s)	2.74
Vericel	0 Sell rating(s)	3 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.57

In the previous week, Rhythm Pharmaceuticals had 8 more articles in the media than Vericel. MarketBeat recorded 14 mentions for Rhythm Pharmaceuticals and 6 mentions for Vericel. Vericel's average media sentiment score of 1.79 beat Rhythm Pharmaceuticals' score of 1.44 indicating that Vericel is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Rhythm Pharmaceuticals	11 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Vericel	5 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive

Rhythm Pharmaceuticals has a beta of 1.92, meaning that its stock price is 92% more volatile than the broader market. Comparatively, Vericel has a beta of 1.06, meaning that its stock price is 6% more volatile than the broader market.

Vericel has higher revenue and earnings than Rhythm Pharmaceuticals. Rhythm Pharmaceuticals is trading at a lower price-to-earnings ratio than Vericel, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Rhythm Pharmaceuticals	$239.92M	30.61	-$196.54M	-$3.11	N/A
Vericel	$276.26M	7.59	$16.52M	$0.47	87.13

Summary

Vericel beats Rhythm Pharmaceuticals on 9 of the 14 factors compared between the two stocks.

Get Vericel News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding VCEL and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

VCEL vs. The Competition

Export

Metric	Vericel	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$2.10B	$3.93B	$7.20B	$12.90B
Dividend Yield	N/A	3.61%	2.54%	11.28%
P/E Ratio	87.13	11.62	273.16	25.45
Price / Sales	7.59	1,396.16	640.19	89.89
Price / Cash	73.72	106.39	76.74	53.00
Price / Book	5.66	16.53	12.98	6.14
Net Income	$16.52M	-$22.80M	$3.48B	$348.86M
7 Day Performance	-4.05%	-0.31%	0.13%	-0.80%
1 Month Performance	-13.99%	9.80%	7.08%	4.13%
1 Year Performance	12.62%	55.66%	24.67%	15.17%

Vericel Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
VCEL Vericel	3.7798 of 5 stars	$40.95 -0.6%	$58.40 +42.6%	+12.6%	$2.10B	$276.26M	87.13	300	Positive News
APGE Apogee Therapeutics	1.6401 of 5 stars	$134.79 +0.0%	$124.43 -7.7%	+271.1%	$8.38B	N/A	N/A	91	News Coverage Positive News
TGTX TG Therapeutics	3.4374 of 5 stars	$56.01 +3.2%	$63.00 +12.5%	+83.9%	$8.31B	$616.29M	20.44	290	Positive News
IBRX ImmunityBio	2.2866 of 5 stars	$7.58 -2.7%	$14.20 +87.3%	+244.0%	$8.26B	$113.29M	N/A	590
ALKS Alkermes	2.2159 of 5 stars	$48.87 +1.1%	$54.56 +11.6%	+63.7%	$8.11B	$1.67B	128.61	2,050

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:VCEL) was last updated on 8/30/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Vericel (VCEL) Competitors

VCEL vs. APGE, TGTX, IBRX, ALKS, and RYTM

How does Vericel compare to Apogee Therapeutics?

Summary

How does Vericel compare to TG Therapeutics?

Summary

How does Vericel compare to ImmunityBio?

Summary

How does Vericel compare to Alkermes?

Summary

How does Vericel compare to Rhythm Pharmaceuticals?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

VCEL vs. The Competition

Vericel Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Vericel (VCEL) Competitors

VCEL vs. APGE, TGTX, IBRX, ALKS, and RYTM

How does Vericel compare to Apogee Therapeutics?

Do analysts recommend VCEL or APGE?

Does the media refer more to VCEL or APGE?

Is VCEL or APGE more profitable?

Which has better earnings and valuation, VCEL or APGE?

Which has more risk and volatility, VCEL or APGE?

Do institutionals & insiders hold more shares of VCEL or APGE?

Summary

How does Vericel compare to TG Therapeutics?

Does the media refer more to VCEL or TGTX?

Do analysts rate VCEL or TGTX?

Which has stronger valuation & earnings, VCEL or TGTX?

Is VCEL or TGTX more profitable?

Do institutionals and insiders believe in VCEL or TGTX?

Which has more volatility & risk, VCEL or TGTX?

Summary

How does Vericel compare to ImmunityBio?

Which has higher valuation and earnings, IBRX or VCEL?

Is IBRX or VCEL more profitable?

Which has more risk & volatility, IBRX or VCEL?

Do insiders & institutionals believe in IBRX or VCEL?

Do analysts recommend IBRX or VCEL?

Does the media favor IBRX or VCEL?

Summary

How does Vericel compare to Alkermes?

Is VCEL or ALKS more profitable?

Does the media refer more to VCEL or ALKS?

Do analysts rate VCEL or ALKS?

Which has more risk & volatility, VCEL or ALKS?

Do insiders & institutionals have more ownership in VCEL or ALKS?

Which has stronger valuation and earnings, VCEL or ALKS?

Summary

How does Vericel compare to Rhythm Pharmaceuticals?

Is RYTM or VCEL more profitable?

Do analysts prefer RYTM or VCEL?

Does the media refer more to RYTM or VCEL?

Which has more risk and volatility, RYTM or VCEL?

Which has better earnings and valuation, RYTM or VCEL?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

VCEL vs. The Competition

Vericel Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools